<h2 id="what-is-rocuronium-">What is Rocuronium? <sup id="fnref:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>An intermediate-acting non-depolarizing neuromuscular blocking drug (NDMR) used for rapid induction and intubation.</li>
  <li>Popular for short and intermediate procedures due to its rapid onset and ability to induce neuromuscular block quickly.</li>
</ul>
<h2 id="mechanism-of-action--pharmacokinetics-">Mechanism of Action &amp; Pharmacokinetics <sup id="fnref:1:1" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup><sup id="fnref:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></h2>
<ul>
  <li>Rocuronium competitively binds to nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thereby inhibiting muscle contraction.</li>
  <li>Onset time is 60-80 seconds for an intubating dose (approximately 0.6 mg/kg).</li>
  <li>Duration of action: 35-45 minutes.</li>
  <li>Dosage is typically based on <strong>ideal body weight (IBW)</strong> for intubation and <strong>lean body weight (LBW)</strong> for maintenance infusions, as rocuronium distributes primarily in lean tissue. This approach helps to avoid overdosing in obese patients, which could prolong the duration of action. <sup id="fnref:2:1" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></li>
</ul>
<h2 id="pharmacodynamics-">Pharmacodynamics <sup id="fnref:1:2" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<h3 id="cardiovascular">Cardiovascular</h3>
<ul>
  <li>Few cardiovascular effects.
    <h3 id="respiratory">Respiratory</h3>
  </li>
  <li>Paralysis impairs airway protection and respiration. Reversal of paralysis must be achieved prior to airway removal.
    <h3 id="neurological">Neurological</h3>
  </li>
  <li>Adequate depth of anesthesia must be maintained to minimize the risk of awareness during paralysis.</li>
</ul>
<h2 id="indications-">Indications <sup id="fnref:1:3" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Rapid sequence induction and intubation (opens vocal cords, improves laryngoscopy view).</li>
  <li>Maintenance of neuromuscular block during surgery.</li>
  <li>Alternative to succinylcholine in situations where a rapid onset is required without the associated side effects of depolarizing agents.</li>
</ul>
<h2 id="dosage-">Dosage <sup id="fnref:1:4" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li><strong>Intubation Dose:</strong> 0.6 mg/kg based on <strong>ideal body weight (IBW)</strong>, 1.2 mg/kg for rapid sequence intubation based on <strong>ideal body weight (IBW)</strong>.</li>
  <li><strong>Maintenance Infusion:</strong> Dose adjusted based on <strong>lean body weight (LBW)</strong> to avoid prolonged neuromuscular block, particularly in obese patients. <sup id="fnref:2:2" role="doc-noteref"><a href="#fn:2" class="footnote" rel="footnote">2</a></sup></li>
</ul>
<h2 id="contraindications-">Contraindications <sup id="fnref:1:5" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Hypersensitivity to rocuronium or any component of the formulation.</li>
  <li>Use with caution in patients with known neuromuscular disorders.</li>
</ul>
<h2 id="complications-">Complications <sup id="fnref:1:6" role="doc-noteref"><a href="#fn:1" class="footnote" rel="footnote">1</a></sup></h2>
<ul>
  <li>Prolonged neuromuscular block, especially in patients with renal impairment.</li>
  <li>Anaphylaxis, though rare, has been reported.</li>
</ul>
<h2 id="references">References</h2>
<div class="footnotes" role="doc-endnotes">
  <ol>
    <li id="fn:1" role="doc-endnote">
      <p>Birdi T, Sullivan P. Ottawa Anesthesia Primer. Toronto, Ontario: Echo Book Publishing; 2012. <a href="#fnref:1" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:1:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:1:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a> <a href="#fnref:1:3" class="reversefootnote" role="doc-backlink">&#8617;<sup>4</sup></a> <a href="#fnref:1:4" class="reversefootnote" role="doc-backlink">&#8617;<sup>5</sup></a> <a href="#fnref:1:5" class="reversefootnote" role="doc-backlink">&#8617;<sup>6</sup></a> <a href="#fnref:1:6" class="reversefootnote" role="doc-backlink">&#8617;<sup>7</sup></a></p>
    </li>
    <li id="fn:2" role="doc-endnote">
      <p>De Baerdemaeker LE, Mortier EP, Struys MM. Pharmacokinetics in obese patients. Continuing Education in Anaesthesia Critical Care &amp; Pain. 2004 Oct;4(5):152–5. <a href="#fnref:2" class="reversefootnote" role="doc-backlink">&#8617;</a> <a href="#fnref:2:1" class="reversefootnote" role="doc-backlink">&#8617;<sup>2</sup></a> <a href="#fnref:2:2" class="reversefootnote" role="doc-backlink">&#8617;<sup>3</sup></a></p>
    </li>
  </ol>
</div>